Evidence map›Paper›PMID 36329648›Full record

ArticleJournal of medical virology2023

Effectiveness of SARS-CoV-2-inactivated vaccine and the correlation to neutralizing antibodies: A test-negative case-control study.

Can Liu, Jiawei Zhang, Yongbin Zeng, Chun Huang, Falin Chen, Yingping Cao, Siying Wu, Donghong Wei, Zhong Lin, Yali Zhang and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Can LiuDepartment of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jiawei ZhangDepartment of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yongbin ZengDepartment of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Chun HuangFujian Medical Association, Fuzhou, China.
Falin ChenDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Yingping CaoDepartment of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, China.
Siying WuDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
Donghong WeiDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
Zhong LinFujian Provincial Center for Disease Control and Prevention, Fuzhou, China.
Yali ZhangThe State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health and School of Life Science, Xiamen University, Xiamen, China.
Ling ZhangDepartment of Laboratory Medicine, Land Force No.73 Group Army Hospital of PLA, Xiamen, China.
Jing TengDepartment of Laboratory Medicine, Beijing University of Chinese Medicine Xiamen Hospital, Xiamen, China.
Zishun LiDepartment of Laboratory Medicine, The Third Hospital of Xiamen, Xiamen, China.
Guolin HongDepartment of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen Key Laboratory of Genetic Testing, School of Medicine, Xiamen University, Xiamen, China.
Tianci YangCenter of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Huiming YeDepartment of Clinical Laboratory, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
Haijian TuDepartment of Laboratory Medicine, Affiliated Hospital of Putian University, Putian, China.
Yupeng XiaoDepartment of Clinical Laboratory, Putian Municipal First Hospital, Putian, China.
Lishan HuangFujian Provincial Healthcare Center, Fuzhou, China.
Caorui LinDepartment of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Tianbin ChenDepartment of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yanqin DengFujian Provincial Center for Disease Control and Prevention, Fuzhou, China.
Qishui OuDepartment of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.ORCID 0000-0002-9923-3212
Jinming LiNational Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 breakthrough infection in highly vaccinated populations raises study on the effectiveness for inactivated vaccine, including effectiveness of the vaccine dose, the continuance of effectiveness, the effectiveness against severe/critical coronavirus disease 2019 and against secondary attacks. A population of 10 870 close contacts were investigated in a Delta variant's epidemic. The effectiveness of vaccination was estimated in a test-negative case-control study. In addition, serum was used to detect neutralizing antibodies, to explore their correlation to effectiveness. The vaccine effectiveness (VE) values were estimated for populations aged 12 years or older. The overall adjusted VE was 56.2% and a two-dose vaccine was more effective than a one-dose vaccine (56.7% vs. 43.8%). In addition, the population that got the second dose vaccine within 2 months showed higher VE than the population vaccinated for longer than 2 months (61.5% vs. 52.3%). Among the population who vaccinated 2 doses or within 2 months, a higher level of neutralizing antibodies was observed. For infected cases, vaccinated populations showed lower rates of transmission (2.63% vs. 4.36%). Further, those vaccinated cases, who were not found causing transmission, had a higher level of antibodies. The study provided a full view of the effectiveness of inactivated vaccines in a real-world setting. The time-related VE against infection and lower transmission of breakthrough vaccinated cases were observed, which may indicate that a necessity of a booster vaccine to maintain the effectiveness and high level of neutralizing antibody.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralCase-Control StudiesHumansSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesinactivated vaccineneutralizing antibodiesSARS-CoV-2vaccine effectiveness

Identifiers

PMID36329648
PMCPMC9877865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.